Outlook Therapeutics Statistics
Want to see OTLK full AI Analyst Report?
Outlook Therapeutics (OTLK) Stock Statistics & Valuation Metrics
Total Valuation
Outlook Therapeutics has a market cap or net worth of $100.54M. The enterprise value is $224.61M.
- Market Cap
- $100.54M
- Enterprise Value
- $224.61M
Share Statistics
Outlook Therapeutics has 243,447,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 243,447,560
- Owned by Insiders
- 10.51%
- Owned by Institutions
- 7.12%
Financial Efficiency
Outlook Therapeutics’s return on equity (ROE) is 1.94 and return on invested capital (ROIC) is -2357.61%.
- Return on Equity (ROE)
- 1.94
- Return on Assets (ROA)
- -3.36
- Return on Invested Capital (ROIC)
- -2357.61%
- Return on Capital Employed (ROCE)
- 2.46
- Revenue Per Employee
- 83.15K
- Profits Per Employee
- -3.67M
- Employee Count
- 17
- Asset Turnover
- 0.08
- Inventory Turnover
- 0.23
Valuation Ratios
The current PE Ratio of Outlook Therapeutics is -0.38. Outlook Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.38
- PS Ratio
- -86.44
- PB Ratio
- -5.43
- Price to FCF
- -1.76
- Price to Operating Cash Flow
- -0.99
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Outlook Therapeutics had revenue of 1.41M and earned -62.42M in profits. Earnings per share was -1.79.
- Revenue
- 1.41M
- Gross Profit
- 657.21K
- Operating Income
- -67.06M
- Pretax Income
- -63.98M
- Net Income
- -62.42M
- EBITDA
- -63.58M
- Earnings Per Share (EPS)
- -1.79
Cash Flow
In the last 12 months, operating cash flow was -57.13M and capital expenditures 0, giving a free cash flow of -57.13M billion.
- Operating Cash Flow
- -57.13M
- Free Cash Flow
- -57.13M
- Free Cash Flow per Share
- -0.42
Dividends & Yields
Outlook Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -56.82%
- Earnings Yield
- -108.23%
Stock Price Statistics
- Beta
- 1.90
- 52-Week Price Change
- -71.90%
- 50-Day Moving Average
- 0.56
- 200-Day Moving Average
- 0.67
- Relative Strength Index (RSI)
- 32.59
- Average Volume (3m)
- 6.72M
Important Dates
Outlook Therapeutics upcoming earnings date is Dec 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Dec 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Outlook Therapeutics as a current ratio of 0.38, with Debt / Equity ratio of -93.81%
- Current Ratio
- 0.38
- Quick Ratio
- 0.31
- Debt to Market Cap
- 1.11
- Net Debt to EBITDA
- -0.35
- Interest Coverage Ratio
- -236.86
Taxes
In the past 12 months, Outlook Therapeutics has paid -1.55M in taxes.
- Income Tax
- -1.55M
- Effective Tax Rate
- 0.02
Enterprise Valuation
Outlook Therapeutics EV to EBITDA ratio is -1.73, with an EV/FCF ratio of -1.89.
- EV to Sales
- -92.62
- EV to EBITDA
- -1.73
- EV to Free Cash Flow
- -1.89
- EV to Operating Cash Flow
- -1.89
Balance Sheet
Outlook Therapeutics has $11.24M in cash and marketable securities with $18.43M in debt, giving a net cash position of -$7.19M billion.
- Cash & Marketable Securities
- $11.24M
- Total Debt
- $18.43M
- Net Cash
- -$7.19M
- Net Cash Per Share
- -$0.03
- Tangible Book Value Per Share
- -$0.08
Margins
Gross margin is 195.64%, with operating margin of 4783.05%, and net profit margin of 5254.81%.
- Gross Margin
- 195.64%
- Operating Margin
- 4783.05%
- Pretax Margin
- 5384.94%
- Net Profit Margin
- 5254.81%
- EBITDA Margin
- 5353.27%
- EBIT Margin
- 5362.21%
Analyst Forecast
The average price target for Outlook Therapeutics is $10.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $10.50
- Price Target Upside
- 2442.37% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 2
- AI Score
- 48

